Spots Global Cancer Trial Database for mitoxantrone
Every month we try and update this database with for mitoxantrone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating Mitoxantrone in Multiple Sclerosis | NCT00146159 | Secondary Progr... | Mitoxantrone | 18 Years - 55 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Taxotere Prostate Cancer New Indication Registration Trial in China | NCT00436839 | Prostatic Neopl... | Docetaxel Mitoxantrone Prednisone | - | Sanofi | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | NCT02101853 | Recurrent B Acu... | Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00109837 | Leukemia | filgrastim cyclophosphamid... cytarabine daunorubicin dexamethasone doxorubicin leucovorin mercaptopurine methotrexate mitoxantrone Asparaginase prednisone thioguanine vincristine radiation thera... allopurinol bactrim | 18 Years - 64 Years | SWOG Cancer Research Network | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | NCT01700946 | Recurrent B-Cel... Recurrent Child... | dexamethasone vincristine sul... rituximab clofarabine cyclophosphamid... etoposide aldesleukin pegaspargase methotrexate mercaptopurine cytarabine mitoxantrone teniposide vinblastine natural killer ... laboratory biom... therapeutic hyd... allogeneic hema... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | NCT00304291 | Neuromyelitis O... Myelitis, Trans... Demyelinating A... Autoimmune Dise... | Mitoxantrone | 18 Years - 55 Years | State University of New York at Buffalo | |
| Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | NCT02631252 | Leukemia, Acute... | Hydroxychloroqu... Mitoxantrone Etoposide | 18 Years - 80 Years | University of Pittsburgh | |
| Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | NCT00556127 | Diffuse Large B... POOR PROGNOSIS | Rituximab Epirubicin Cyclophosphamid... Vincristine Prednisone Granulocyte-col... Mitoxantrone Cytarabine ARA-... Dexamethasone Carmustine BCNU Etoposide Melphalan Radiotherapy PBSC reinfusion | 18 Years - 60 Years | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | NCT05313958 | Leukemia, Monoc... Pediatric AML | Cladribine G-CSF Cytarabine Idarubicin Mitoxantrone Sorafenib | 1 Month - 14 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Taxotere Prostate Cancer New Indication Registration Trial in China | NCT00436839 | Prostatic Neopl... | Docetaxel Mitoxantrone Prednisone | - | Sanofi | |
| LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | NCT00526305 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone L-Asparaginase Mitoxantrone Cytosine Arabin... Hydrocortisone Mercaptopurine Cyclophosphamid... Dexamethasone | - 65 Years | PETHEMA Foundation | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT00744081 | AML | Glivec Mitoxantrone Topotecan AraC | 18 Years - | Goethe University | |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | NCT03591510 | FLT3-mutated Ac... | Midostaurin Fludarabine Cytarabine Daunorubicin or... Mitoxantrone Etoposide | 3 Months - 17 Years | Novartis | |
| Brentuximab Vedotin + Re-induction Chemotherapy for AML | NCT01830777 | Acute Myelogeno... | Brentuximab Ved... Mitoxantrone Etoposide Cytarabine | 18 Years - | Massachusetts General Hospital | |
| Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | NCT00193479 | Non-Hodgkins Ly... | Cyclophosphamid... Mitoxantrone Vincristine Prednisone Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer | NCT00417079 | Neoplasms Prostatic Neopl... | cabazitaxel (XR... mitoxantrone prednisone | 18 Years - | Sanofi | |
| Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | NCT00906945 | Leukemia, Myelo... | G-CSF Plerixafor Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | NCT00254410 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Mitoxantrone Rituximab Filgrastim | - 70 Years | M.D. Anderson Cancer Center | |
| Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) | NCT00661492 | Androgen-indepe... | cetuximab Mitoxantrone | 18 Years - | US Oncology Research | |
| Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | NCT00656084 | Relapsed or Ref... | gemcitabine mitoxantrone rituximab | 18 Years - | US Oncology Research | |
| Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma | NCT00002259 | Sarcoma, Kaposi HIV Infections | Mitoxantrone hy... | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | NCT02535806 | Acute Lymphobla... Lymphoblastic L... | Velcade Methotrexate Methotrexate / ... Dexamethasone Mitoxantrone Vincristine Pegaspargase | 1 Year - 39 Years | Children's Mercy Hospital Kansas City | |
| AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | NCT00770848 | Cancer Castrate-Resist... Mestastatic Pro... Prostate Cancer | AMG 102 AMG 102 Mitoxantrone Placebo Prednisone | 18 Years - | Amgen | |
| Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | NCT01184898 | AML | Sirolimus Mitoxantrone Etoposide Cytarabine | 18 Years - | Thomas Jefferson University | |
| Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | NCT02583893 | Recurrent Adult... Secondary Acute... Untreated Adult... | Sirolimus Mitoxantrone Etoposide Cytarabine | 18 Years - | Thomas Jefferson University | |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | NCT00119730 | Mantle Cell Lym... | Fludarabine Mitoxantrone Rituximab Zevalin | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | NCT00124566 | Prostate Cancer | Irofulven Prednisone Mitoxantrone Capecitabine Irofulven | 18 Years - | Eisai Inc. | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06007911 | Relapsed Adult ... Refractory AML | Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Venetoclax Dose... Venetoclax Dose... Cladribine Cytarabine (Cla... Cytarabine (CLA... Mitoxantrone Granulocyte Col... | 18 Years - | Medical College of Wisconsin | |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT00744081 | AML | Glivec Mitoxantrone Topotecan AraC | 18 Years - | Goethe University | |
| Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | NCT00193479 | Non-Hodgkins Ly... | Cyclophosphamid... Mitoxantrone Vincristine Prednisone Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | NCT04195945 | Acute Myeloid L... Myeloid Neoplas... | Liposome-encaps... Cladribine Cytarabine Recombinant Gra... Mitoxantrone Questionnaire A... Quality-of-Life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02728050 | Acute Biphenoty... Acute Myeloid L... de Novo Myelody... Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Filgrastim Laboratory Biom... Quality-of-Life... Mitoxantrone Sorafenib | 18 Years - 60 Years | University of Washington | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00004001 | Prostate Cancer | docetaxel estramustine mitoxantrone prednisone | 18 Years - | SWOG Cancer Research Network | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias | NCT00882076 | Leukemia | Clofarabine Mitoxantrone Etoposide | 18 Years - 70 Years | Milton S. Hershey Medical Center | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT00744081 | AML | Glivec Mitoxantrone Topotecan AraC | 18 Years - | Goethe University | |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | NCT00060684 | Lymphoma, Low-G... Lymphoma, Small... Lymphoma, Mixed... Lymphoma, Small... | Pixantrone (BBR... fludarabine dexamethasone rituximab | 18 Years - | CTI BioPharma | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | NCT00683475 | Prostate Cancer | IMC-A12 Mitoxantrone Prednisone IMC-1121B (ramu... | 18 Years - | Eli Lilly and Company | |
| A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis | NCT03258320 | Prostate Cancer... | Cabazitaxel, Do... | 40 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Study Evaluating Mitoxantrone in Multiple Sclerosis | NCT00146159 | Secondary Progr... | Mitoxantrone | 18 Years - 55 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | NCT02198482 | Acute Myeloid L... High-risk Myelo... | Volasertib Cytarabine Daunorubicin Mitoxantrone | 18 Years - | University of Ulm | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | NCT00180128 | Leukemia, Promy... | all-trans retin... idarubicin mitoxantrone daunorubicin cytarabine | 16 Years - | Technische Universität Dresden | |
| Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | NCT03118466 | AML | Etoposide Cytarabine Lenalidomide Mitoxantrone | 18 Years - 70 Years | Massachusetts General Hospital | |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | NCT03735446 | Acute Myeloid L... Myelodysplastic... | Prexasertib Mitoxantrone Etoposide Cytarabine | 18 Years - | Dana-Farber Cancer Institute | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02728050 | Acute Biphenoty... Acute Myeloid L... de Novo Myelody... Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Filgrastim Laboratory Biom... Quality-of-Life... Mitoxantrone Sorafenib | 18 Years - 60 Years | University of Washington | |
| Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00452387 | Metastatic Pros... | Mitoxantrone Prednisone Sorafenib | 18 Years - | Accelerated Community Oncology Research Network | |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | NCT00119730 | Mantle Cell Lym... | Fludarabine Mitoxantrone Rituximab Zevalin | 18 Years - | Dana-Farber Cancer Institute | |
| Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | NCT00577993 | Lymphoma | Fludarabine Novantrone Decadron Rituximab Interferon Doxorubicin Vincristine Bleomycin Cyclophosphamid... Etoposide Cisplatin Ara-C Methyl-Predniso... Procarbazine Prednisone | - 76 Years | M.D. Anderson Cancer Center | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| Lenalidomide Plus Chemotherapy for AML | NCT01681537 | Acute Myelogeno... | Lenalidomide Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Massachusetts General Hospital | |
| A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | NCT02200978 | Childhood Acute... | ATO RIF ATRA mitoxantrone Ara-C MTX 6MP intrathecal inj... | - 16 Years | South China Children's Leukemia Group | |
| Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas | NCT00002003 | Lymphoma, Non-H... HIV Infections | Mitoxantrone hy... Etoposide | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas | NCT00002003 | Lymphoma, Non-H... HIV Infections | Mitoxantrone hy... Etoposide | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | NCT00059631 | Prostate Cancer | Mitoxantrone (N... Bortezomib (PS-... | 18 Years - | M.D. Anderson Cancer Center | |
| IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) | NCT01027923 | Leukemia, Myelo... | Plerixafor Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | NCT00901927 | Follicular Lymp... | Bendamustine Mitoxantrone Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | NCT06429449 | Leukemia Myeloid Leukemi... Monocytic Leuke... | Venetoclax Azacitidine Mitoxantrone | 18 Years - 80 Years | University of Colorado, Denver | |
| Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | NCT02306291 | Leukemia, Myelo... | GMI-1271 Mitoxantrone Etoposide Cytarabine Idarubicin | 18 Years - | GlycoMimetics Incorporated | |
| Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | NCT00290511 | Lymphoma | Fludarabine Mitoxantrone Rituximab Zevalin Dexamethasone | 60 Years - | M.D. Anderson Cancer Center | |
| Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) | NCT00661492 | Androgen-indepe... | cetuximab Mitoxantrone | 18 Years - | US Oncology Research | |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | NCT02101853 | Recurrent B Acu... | Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Optimal Treatment Strategy Based on for Pediatric AML | NCT02848183 | Pediatric Acute... | Cytarabine Idarubicin Mitoxantrone Etoposide Hematopoietic s... | - 18 Years | Samsung Medical Center | |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT00744081 | AML | Glivec Mitoxantrone Topotecan AraC | 18 Years - | Goethe University | |
| Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer | NCT00447473 | Prostatic Neopl... | GM-CSF Ketoconazole Mitoxantrone | 18 Years - | The Methodist Hospital Research Institute | |
| A Study of Olaratumab (IMC-3G3) in Prostate Cancer | NCT01204710 | Prostate Cancer | Olaratumab Mitoxantrone Prednisone | 18 Years - | Eli Lilly and Company | |
| S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00004001 | Prostate Cancer | docetaxel estramustine mitoxantrone prednisone | 18 Years - | SWOG Cancer Research Network | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma | NCT01578343 | Mantle Cell Lym... | Fludarabine, Mi... | 19 Years - 75 Years | Samsung Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
